Samantha Budd Haeberlein, the Biogen senior executive who supervised the development and controversial approval of the Alzheimer’s treatment Aduhelm, has left the company, STAT has learned.
Budd Haeberlein’s employment at Biogen ended on Friday, according to two former Biogen employees with knowledge of the situation. Her departure was characterized as voluntary, coinciding with the desire of Chris Viehbacher, Biogen’s new CEO, to shake up the company’s executive ranks after Aduhelm’s costly commercial failure.
“Over more than eight years at Biogen, Samantha made many important scientific contributions to the neurodegeneration field — most notably the advancement of our Alzheimer’s disease pipeline and the development of Aduhelm,” said a Biogen spokesperson, confirming Budd Haeberlein’s departure. “We wish her the best in her future endeavors.”
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect